Inclusion Criteria

- INCLUSION CRITERIA:

Patients must meet all of the following eligibility criteria.

Tissue diagnosis of: follicular small cleaved cell, or follicular mixed lymphoma with
surface IgM, IgG or IgA phenotype with a monoclonal heavy and light chain. Pathology
slides must be submitted to the NIH Pathology Department for review.

Stage III or IV lymphoma.

Only previously untreated patients are eligible.

Previous treatment with radiation alone (less than TBI) is permissible.

A single peripheral lymph node of at least 2 cm size accessible for biopsy/harvest.

Karnofsky status greater than or equal to 70 percent.

Life expectancy of greater than 1 year.

Serum creatinine less than or equal to 1.5 mg per dl unless felt to be secondary to
lymphoma.

Bilirubin less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma or
Gilbert's disease. SGOT/SGPT less than or equal to 3.5 times upper limit of normal.

Ability to give informed consent. Ability to return to clinic for adequate follow-up for
the period that the protocol requires.

EXCLUSION CRITERIA:

Prior total body irradiation.

Presence of antibodies to HIV, hepatitis B surface antigen or other active infectious
process.

Pregnancy or lactation. Fertile men and women must plan to use effective contraception.
A beta-HCG level will be obtained in women of child-bearing potential.

Patients with previous or concomitant malignancy, regardless of site, except curatively
treated squamous or basal cell carcinoma of the skin, or effectively treated carcinoma in
situ of the cervix.

Patients unwilling to give informed consent.

Failure to meet any of the inclusion criteria.

Any medical or psychiatric condition that in the opinion of the protocol chairman would
compromise the patient's ability to tolerate this treatment will be excluded from this
protocol.

Patient with CNS lymphoma (current or previously treated) will not be eligible.